| Autor: |
Daniel Leung, Eugene Yu-hin Chan, Xiaofeng Mu, Jaime S Rosa Duque, Samuel MS Cheng, Fanny Tsz-wai Ho, Pak-chiu Tong, Wai-ming Lai, Matthew HL Lee, Stella Chim, Issan YS Tam, Leo CH Tsang, Kelvin KH Kwan, Yuet Chung, Howard HW Wong, Amos MT Lee, Wing Yan Li, Summer TK Sze, Jennifer HY Lam, Derek HL Lee, Sau Man Chan, Wenwei Tu, Malik Peiris, Alison Lap-tak Ma, Yu Lung Lau |
| Rok vydání: |
2022 |
| ISSN: |
0480-0133 |
| DOI: |
10.1101/2022.09.14.22279916 |
| Popis: |
BackgroundPatients with kidney diseases are at risk of severe complications from COVID-19, yet little is known about the effectiveness of COVID-19 vaccines in children and adolescents with kidney diseases.MethodsWe investigated the immunogenicity and safety of an accelerated, 3-dose primary series of COVID-19 vaccines among 64 pediatric chronic kidney disease patients (mean age 12.2; 32 male) with or without immunosuppression, dialysis, or kidney transplant. CoronaVac was given to those aged ResultsAntibody responses including S-RBD IgG (90.9-100% seropositive) and surrogate virus neutralization (geometric mean sVNT% level, 78.6-94.0%) were significantly elicited by 3 doses of any vaccine. T cell responses were also elicited. Weaker neutralization responses were observed among kidney transplant recipients and non-dialysis children receiving rituximab for glomerular diseases. Neutralization was reduced against Omicron BA.1 compared to wild-type (post-dose 3 sVNT% level; 84% vs 27.2%; pConclusionsOur findings support that an accelerated 3-dose primary series with CoronaVac and BNT162b2 is safe and immunogenic in young children and adolescents with kidney diseases.TRIAL REGISTRATIONClinicaltrials.govNCT04800133SIGNIFICANCE STATEMENTLittle is known about the effectiveness of COVID-19 vaccines in children and adolescents with kidney diseases. This paper describes the antibody and T cell responses of 3 doses of CoronaVac or BNT162b2, the top 2 COVID-19 vaccines distributed worldwide, by an accelerated regimen in patients with kidney diseases aged 1-18 years. Antibody and T cell responses were significantly elicited by either vaccine. Neutralization was reduced against Omicron while T cell response was preserved, which likely confer protection against severe COVID-19. Rate of severe adverse reactions was low in the study. Results confirm that accelerated 3-dose primary series with CoronaVac and BNT162b2 is safe and immunogenic in young children and adolescents with kidney diseases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
